And this NICE cut off is too generous with drugs of marginal cost
effectiveness inflating costs and giving patients small increases in the
length and quality of life at a high opportunity cost. We need a much
stricter cut off and a policy to tell industry to bring better=more cost
effective products to market. You can see more on this in the recent
report of the Select Committee on Health of the House of Commons (report
on "top ups" May 2009.) where I worked as an adviser. A short paper to
appear in the Journal of the Royal Society of Medicine by Maynard and
Bloor follows.
Alan
Adam Oliver wrote:
>
> From Tim Jost:
>
>
>
> http://www.washingtonpost.com/wp-dyn/content/article/2009/05/22/AR2009052202370_pf.html
>
>
>
>
>
>
> Please access the attached hyperlink for an important electronic
> communications disclaimer:
> http://www.lse.ac.uk/collections/secretariat/legal/disclaimer.htm
|